Takeout offer - questions for shareholders...I believe that a takeout offer will be forthcoming in the next 60 -90 days from a suitor. (likely Valeant or Endo) My logic is: why pay an up front fee, plus milestones, plus revenue sharing when you can take a shot at the whole company without really risking a future partnership if the bid goes south? What's a reasonable up front amount for the other 95% of the world? 40 - 60mm? (Endo paid 38mm with only phase 2 data in hand - we are potentially a few months away from BLA submission, with accelerated only another 6 months after that for approval). What's a milestone for FDA approval? another 50m? Revenue based milestones of another 100 -200mm? Revenue sharing of another 25% to 40% of 200mm - 1B annually? That's potentially anywhere from 90mm (first year) as high as 400mm a year in the years following that a pharma could pay out. Why not get the whole nut with a hostile bid? When we are this close to the promised land, what would you shareholders part with your shares for? beech